Seminars in Oncology
Volume 31, Issue 2 , Pages 220-233 , April 2004

Aerorespiratory tract cancer in older patients

  • Aqeel A Gillani

      Affiliations

    • Division of Hematology/Oncology, The University of Vermont, Burlington, VT, USA
    • Corresponding Author InformationAddress reprint requests to Aqeel A. Gillani, MD, Division of Hematology/Oncology, The University of Vermont, UHC Campus, St Joseph 3400, 1 South Prospect St, Burlington, VT 05401 USA
    • ,
  • Steven M Grunberg

      Affiliations

    • Division of Hematology/Oncology, The University of Vermont, Burlington, VT, USA

References 

  1. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001;61(suppl 1):3–13
  2. Shields TW. Surgical therapy for carcinoma of the lung. Clin Chest Med. 1993;14:121–147
  3. Grunberg SM, Bibawi SE. Lung Cancer. In:  Hunter CP,  Johnson KA,  Muss HB editor. Cancer in the Elderly. New York, NY: Marcel Dekker, Inc; 2000;p. 345–360
  4. O’Rourke MA, Feussner JR, Feigl P, et al.  Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly. JAMA. 1987;258:921–926
  5. North-Eastern Italian Oncology Group-Neoplasms of the Elderly Committee . Clinical characteristics, diagnosis and treatment of elderly patients with lung cancer at non-surgical institutions (A multicenter study). Tumori. 1990;75:429–433
  6. Smith TJ, Penberthy L, Desch CE, et al.  Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995;13:235–252
  7. Jazieh AR, Kayasa MJ, Sethuraman G, et al.  Disparities in surgical resection of early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:1173–1176
  8. Polednak AP. Disparities in surgical treatment of early-stage non-small-cell lung cancer. Yale J Biol Med. 2001;74:309–314
  9. Yellin A, Benfield JR. Surgery for bronchogenic carcinoma in the elderly. Am Rev Respir Dis. 1985;131:197
  10. van Rens MT, de la Riviere AB, Elbers HR, et al.  Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000;117:374–379
  11. Ishida T, Yokoyama H, Kaneko S, et al.  Long-term results of operation for non-small cell lung cancer in the elderly. Ann Thorac Surg. 1990;50:919–922
  12. Shirakusa T, Tsutsui M, Iriki N, et al.  Results of resection for bronchogenic carcinoma in patients over the age of 80. Thorax. 1989;44:189–191
  13. Pagni S, Federico JA, Ponn RB. Pulmonary resection for lung cancer in oc14. togenarians. Ann Thorac Surg. 1997;63:785–789
  14. Bernard A, Ferrand L, Hagry O, et al.  Identification of prognostic factors determining risk groups for lung resection. Ann Thorac Surg. 2000;70:1161–1167
  15. Ginsberg RJ, Hill LD, Eagan RT, et al.  Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc. 1983;86:654–658
  16. Basche M, Kelly K. Treatment of non-small-cell lung cancer in older persons. Oncology. 2003;17:31–39
  17. Dyszkiewicz W, Pawlak K, Gasiorowski L. Early post-pneumonectomy complications in the elderly. Eur J Cardiothorac Surg. 2000;17:246–250
  18. Landreneau RJ, Sugarbaker DJ, Mack MJ, et al.  Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:691–698
  19. Furuta M, Hayakawa K, Katano S, et al.  Radiation therapy for stage I-II non-small cell lung cancer in patients aged 75 years and older. Jpn J Clin Oncol. 1996;26:95–98
  20. Gauden SJ, Tripcony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer. 2001;32:71–79
  21. Numico G, Russi E, Merlano M. Best supportive care in non-small cell lung cancer (Is there a role for radiotherapy and chemotherapy?). Lung Cancer. 2001;32:213–226
  22. Furuse K, Fukuoka M, Kawahara M, et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  23. Komaki R, Seiferheld W, Curran W, et al.  Sequential vs concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410). Proceedings of the 42nd Annual ASTRO meeting. Int J Radiat Oncol Biol Phys. 2000;48:113; (abstr 5)
  24. Non-Small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer (A meta-analysis using updated data on individual patients from 52 randomized clinical trials). BMJ. 1995;311:899–909
  25. Dillman RO, Herndon J, Seagren SL, et al.  Improved survival in stage III non-small-cell lung cancer (Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial). J Natl Cancer Inst. 1996;88:1210–1215
  26. Dillman RO, Seagren SL, Propert KJ, et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  27. Le Chevalier T. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT) (cisplatin-based chemotherapy (CT) vs no CT in 1867 patients with resected non-small cell lung cancer (NSCLC)). Proc Am Soc Clin Oncol. 2003;22:22; (abstr 6)
  28. Langer CJ, Hsu C, Curran W, et al.  Elderly patients with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy. Secondary analysis of RTOG 9410. Proc Am Soc Clin Oncol. 2002;21:299a; (abstr 1193)
  29. Werner-Wasik M, Scott C, Cox JD. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small cell lung cancer (LA-NSCLC) (Identification of five groups with different survival). Int J Radiat Oncol Biol Phys. 2000;48:1475–1482
  30. Sause W, Kolesar P, Taylor S, et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer (Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group). Chest. 2000;117:358–364
  31. Langer CJ, Hsu C, Curran W, et al.  Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy?. Int J Radiat Oncol Biol Phys. 2001;51:20–21
  32. Atagi S, Furuse K, Kawahara M, et al.  Phase II trail of daily low-dose carboplatin (CBDCA) and radiotherapy (RT) in elderly patients with unresectable locally advanced non-small cell lung cancer (NSCLC). 8th World Conference on Lung Cancer. Lung Cancer. 1997;18(suppl 1):138; abstr 538
  33. Lau DH, Crowley JJ, Gandara DR, et al.  Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998;16:3078–3081
  34. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer (A review of the literature and future directions). Clin Cancer Res. 1998;4:1087–1100
  35. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6(suppl 1):4–7
  36. Frasci G, Lorusso V, Panza N, et al.  Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:2529–2536
  37. Gridelli C, Perrone F, Gallo C, et al.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer (The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial). J Natl Cancer Inst. 2003;95:341–343
  38. Ricci S, Antuzzo A, Galli L. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer (A multicenter phase II study). Lung Cancer. 2000;27:75–80
  39. Hainsworth JD, Burris HA, Litchy S. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer. Cancer. 2000;89:328–333
  40. Langer CJ, Manola J, Bernardo P, et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer (Implications of Eastern Cooperative Oncology Group 5592, a randomized trial). J Natl Cancer Inst. 2002;94:173–181
  41. Kelly K, Giarritta S, Hayes S, et al.  Should older patients receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol. 2001;20:329a; (abstr 1313)
  42. Lilenbaum RC, Herndon J, List M, et al.  Single agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC) (A CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness). Proc Am Soc Clin Oncol. 2002;21: (abstr) A-2
  43. Langer CJ. Lung cancer in the elderly (A therapeutic frontier). In: Lung Cancer Principles and Practice (2nd edition updates). 2:2002;p. 1–15
  44. Page NC, Read WL, Tierney RM. The epidemiology of small cell lung cancer. Proc Am Soc Clin Oncol. 2002;21:305a; (abstr)
  45. Shepherd FA, Amdemichael E, Evans WK. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc. 1994;42:64–70
  46. Dajczman E, Fu LY, Small D. Treatment of small cell lung carcinoma in the elderly. Cancer. 1996;77:2032–2038
  47. Zochbauer-Muller S, Pirker R, Huber H. Treatment of small cell lung cancer patients. Ann Oncol. 1999;10(suppl 6):83–91
  48. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–1441
  49. Turrisi AT. Optimal use of radiotherapy in limited small-cell lung cancer. In: ASCO Educational Book. Alexandria, VA: ASCO; 2000;p. 678–681
  50. Johnson BE, Bridges JD, Sobczeck M, et al.  Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996;14:806–813
  51. Albain KS, Crowley JJ, LeBlanc M, et al.  Determinants of improved outcome in small-cell lung cancer (An analysis of the 2,580-patient Southwest Oncology Group data base). J Clin Oncol. 1990;8:1563–1574
  52. Siu LL, Shepherd FA, Murray N, et al.  Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1996;14:821–828
  53. Pignon JP, Arriagada R, Ihde DC, et al.  A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–1624
  54. Yuen AR, Zou G, Turrisi AT, et al.  Similar outcome of elderly patients in intergroup trial 0096 (Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma). Cancer. 2000;89:1953–1960
  55. Murray N, Grafton C, Shah A, et al.  Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3323–3328
  56. Jeremic B, Shibamoto Y, Acimovic L, et al.  Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma (A phase II study). Cancer. 1998;82:836–841
  57. Oshita F, Kurata T, Kasai T, et al.  Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res. 1995;86:1198–1202
  58. Findlay MP, Griffin AM, Raghavan D, et al.  Retrospective review of chemotherapy for small cell lung cancer in the elderly (Does the end justify the means?). Eur J Cancer. 1991;27:1597–1601
  59. Kelly P, O’Brien AA, Daly P, et al.  Small-cell lung cancer in elderly patients (The case for chemotherapy). Age Aging. 1991;20:19–22
  60. Carney DN, Grogan L, Smit EF, et al.  Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol. 1990;17:49–53
  61. Gatzmeier U, Nenhaus R, Hcckmyer M, et al.  Single agent oral etoposide in advanced NSCLC (chronic daily) and in elderly patients with SCLC. Lung Cancer. 1991;7(suppl 1):102; abstr 374
  62. Smit EF, Carney DN, Harford P, et al.  A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax. 1989;44:631–633
  63. Smit EF, Postmus PE. A phase II study of oral etoposide 100 mg/day for 21 days Q5 weeks in untreated elderly and poor performance status small cell lung cancer patients. Lung Cancer. 1991;7(suppl 1):136; abstr 508
  64. Bork E, Hirsch F, Jeppesen N, et al.  Oral etoposide (VP-16) every 3 wks or continuously to elderly patients with small cell lung cancer (SCLC) (Preliminary results of a randomized study). Lung Cancer. 1997;18(suppl 1):25; abstr 88
  65. Tummarello D, Isidori P, Pasini F, et al.  Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer. 1992;28A:1081–1084
  66. Cascinu S, Del Ferro E, Ligi M, et al.  The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. Am J Clin Oncol. 1997;20:477–478
  67. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer (A stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party). Lancet. 1996;348:563–566
  68. Souhami RL, Spiro SG, Rudd RM, et al.  Five-day oral etoposide treatment for advanced small-cell lung cancer (Randomized comparison with intravenous chemotherapy). J Natl Cancer Inst. 1997;89:577–580
  69. Okamoto H, Watanabe K, Nishiwaki Y. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. J Clin Oncol. 1999;17:3540–3545
  70. Quoix E, Breton JL, Daniel C. Tolerability of a combination of carboplatin and etoposide phosphate in elderly patients with small cell lung cancer. A multicenter phase II clinical trial. Lung Cancer. 2000;29(suppl 1, 131):41
  71. Larive S, Bobaron P. Carboplatin-etoposide in elderly small-cell lung cancer patients (A phase II study). Ann Oncol. 1998;9(suppl 4):105; abstr 504
  72. Evans WK, Radwi A, Tomiak E. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol. 1995;18:149–155
  73. Grunberg SM. Cyclophosphamide and etoposide for non-small cell and small cell lung cancer. Drugs. 1999;58(suppl 3):11–15
  74. Westeel V, Murray N, Gelmon K, et al.  New combination of the old drugs for elderly patients with small-cell lung cancer (A phase II study of the PAVE regimen). J Clin Oncol. 1998;16:1940–1947
  75. Gridelli C, De Vivo R, Monfardini S. Management of small-cell lung cancer in the elderly. Crit Rev Oncol Hematol. 2002;41:79–88
  76. Arrigada R, Le Chevalier T, Borie F, et al.  Randomized trial of prophylactic cranial irradiation (PCI) for patients with small cell lung cancer (SCLC) in complete remission. Proc Am Soc Clin Oncol. 1994;13:334; (abstr 1108)
  77. Arriagada R, Le Chavelier T, Borie F, et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87:183–190
  78. Auperin A, Arrigada R, Pignon JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–484
  79. Johnson BE, Patronas N, Hayes W, et al.  Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer (Further follow-up of 6- to 13-year survivors). J Clin Oncol. 1990;8:48–56
  80. Herskovic AM, Orton CG. Elective brain irradiation for small cell anaplastic lung cancer. Int J Radiat Oncol Biol Phys. 1986;12:427–429
  81. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215–1228
  82. Johnson BE, Becker B, Goff WB, et al.  Neurologic, neuropsychologic and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol. 1985;3:1659–1667
  83. Cull A, Gregor A, Hopwood P. Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer. 1994;8:1067–1074
  84. Gregor A, Cull A, Stephens RJ, et al.  United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC)   Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer (Results of a multicentre randomised trial). Eur J Cancer. 1997;33:1752–1758
  85. Van Oosterhout AG, Ganzevles PG, Wilmink JT. Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys. 1996;34:1037–1044
  86. Conley JC. Introduction. In:  Goldstein JC,  Kashima HK,  Koopman CF editor. Geriatric Otorhinolaryngology. Philadelphia, PA: Decker; 1989;p. 146–147
  87. Muir CS, Fraumeni JF, Doll R. The interpretation of time trends. Cancer Surv. 1994;19–20: 5–1
  88. Lamont DW, Gillis CR, Caird FL. Epidemiology of cancer in the elderly. In:  Caird FL,  Brewin TR editor. Cancer in the Elderly. London: Wright, Butterworth & Co; 1990;p. 9
  89. Pignon T, Horiot JC, Van Den Bogaert W, et al.  No age limit for radical radiotherapy in the in head and neck tumours. Eur J Cancer. 1996;32A:2075–2081
  90. Parkin DM, Muir CS, Whelan SL, et al.  International Agency for Research on cancer. Cancer Incidence in Five Continents. Lyon: IARC Scientific Publication No. 120; 1992; 03–55
  91. Leon X, Quer M, Agudelo D, et al.  Influence of age on laryngeal carcinoma. Ann Otol Rhinol Laryngol. 1998;107:164–169
  92. Sarini J, Fournier C, Lefebvre JL, et al.  Head and neck squamous cell carcinoma in elderly patients. A long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg. 2001;127:1089–1092
  93. Lusinchi A, Bourhis J, Wibault P, et al.  Radiation therapy for head and neck cancers in the elderly. Int J Radiat Oncol Biol Phys. 1990;18:819–823
  94. Koch WM, Patel H, Brennan J, et al.  Squamous cell carcinoma of the head and neck in the elderly. Arch Otolaryngol Head Neck Surg. 1995;121:262–265
  95. Nelson JF, Ship I. Intraoral carcinoma. J Am Diet Assoc. 1971;82:564–568
  96. Jones AS, Husband D, Rowley H. Radical radiotherapy for squamous cell carcinoma of the larynx, oropharynx and hypopharynx (Patterns of recurrence, treatment and survival). Clin Otolaryngol. 1998;23:496–511
  97. Hirano M, Mori K. Management of cancer in the elderly (Therapeutic dilemmas). Otolaryngol Head Neck Surg. 1998;118:110–114
  98. Wei Q, Matanoski GM, Farmer ER, et al.  DNA repair and aging in basal cell carcinoma (A molecular epidemiology study). Proc Natl Acad Sci U S A. 1993;90:1614–1618
  99. Wolf GT. Aging, the immune system, and head and neck cancer. In:  Goldstein JC,  Kashima HK,  Koopman CF editor. Geriatric Otorhinolaryngology. Philadelphia, PA: Decker; 1989;p. 158–165
  100. Hollstein M, Sidransky D, Vogelstein B, et al.  p53 mutations in human cancers. Science. 1991;253:49–53
  101. Boyle JO, Hakim J, Koch W, et al.  The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53:4477–4480
  102. Brennan JA, Boyle JO, Koch WM, et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:712–712
  103. Chin R, Fisher RJ, Smee RI, et al.  Oropharyngeal cancer in the elderly. Int J Radiat Oncol Biol Phys. 1995;32:1007–1016
  104. McGuirt WF, Davis SP. Demographic portrayal and outcome analysis of head and neck cancer surgery in the elderly. Arch Otolaryngol Head Neck Surg. 1995;121:150–154
  105. Harries M, Lund VJ. Head and neck surgery in the elderly (A maturing problem). J Laryngol Otol. 1989;103:306–309
  106. Barzan L, Veronesi A, Caruso G, et al.  Head and neck cancer and ageing (A retrospective study in 438 patients). J Laryngol Otol. 1990;104:634–640
  107. Bridger AG, O’Brien CJ, Lee KK. Advanced patient age should not preclude the use of free-flap reconstruction for head and neck cancer. Am J Surg. 1994;168:425–428
  108. Baumann M. Is curative radiation therapy in the elderly patients limited by increased normal tissue toxicity. Radiother Oncol. 1998;46:225–227
  109. Ampil FL, Mills GM, Stucker FJ, et al.  Radical combined treatment of locally extensive head and neck cancer in the elderly. Am J Otolaryngol. 2001;22:65–69

PII: S0093-7754(03)00670-5

doi: 10.1053/j.seminoncol.2003.12.032

Seminars in Oncology
Volume 31, Issue 2 , Pages 220-233 , April 2004

Article Tools